Biopharmaceutical News and Research

RSS

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

HUYA Bioscience International named winner of bronze Stevie Award

HUYA Bioscience International has been named the winner of a bronze Stevie Award in the Health Products & Services and Pharmaceuticals category in the second annual Asia-Pacific Stevie Awards.

26 May 2015

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and arterial disease, today reported that it has initiated an open-label, multicenter Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E."

26 May 2015

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%.

22 May 2015

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

21 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.

15 May 2015

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Dotmatics, the leading provider of scientific informatics solutions and services for the pharma, biotech, chemicals, agrochemicals and academia announced today that it has appointed LABINDIA as a distributor in India.

14 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

DKSH supports Pfizer’s expansion to Laos

DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their businesses in Asia, has signed an agreement to provide marketing, sales, logistics, distribution, credit management and -collection services to Pfizer in Laos.

12 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

JHL Biotech closes $45.6 million Series C round of financing

JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.

12 May 2015

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.

11 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market.

6 May 2015

Biopharmaceutical News and Research

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

HUYA Bioscience International named winner of bronze Stevie Award

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Omeros receives EMA CHMP positive opinion for Omidria for cataract, IOL replacement surgery

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Galmed reports net loss of $2.5 million for first quarter 2015

Soligenix, Emergent BioSolutions sign development agreement

Research paves way for development of individualized immunotherapy for treating cancer

DKSH supports Pfizer’s expansion to Laos

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

JHL Biotech closes $45.6 million Series C round of financing

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News